The Irish Times

Nestlé in talks to sell skincare business for €9bn

Chief executive Mark Schneider is focusing on coffee, water and pet food for growth

Thu May 16 2019 - 07:56

Outlook positive for life sciences post-Brexit

This country has always been attractive to international life science companies and Brexit throws up opportunities for further growth

Wed Dec 12 2018 - 00:00

European shares fall on US and China trade war fears

Bank of Ireland rallies as Bank of America Merrill Lynch recommends ‘buy’

Mon Jun 18 2018 - 18:56

Shopify tumbles after Citron calls the company a ‘get-rich-quick scheme’

Analyst says Canadian company’s rapid user growth was based off customers who would never become sustainable businesses

Thu Oct 05 2017 - 07:49

Mallinckrodt shorted by US investment group over Acthar drug

Irish-headquartered pharma group accused of ‘murky alliance’ that boosts the price of drug acquired in Questcor deal

Fri May 19 2017 - 13:00

Investors toast strong corporate updates as shares rise across Europe

Dalata hotel group falls sharply in Dublin, with its price down by 2.9 per cent to €5.02

Tue May 09 2017 - 20:10

Valeant increases full-year forecast

Pharmaceutical firm says it is making progress selling assets to reduce debt

Tue May 09 2017 - 16:47

Perrigo makes board changes under pressure from activist investor

Dublin-based drugmaker was urged last year to explore a sale of its prescription business

Tue Feb 07 2017 - 15:19

Debt-laden Valeant Pharmaceuticals cuts full-year forecast

Company reports 11% revenue fall in third quarter on faltering sales and books $1.2bn loss

Tue Nov 08 2016 - 11:24

Mylan listens to Hillary Clinton and cuts EpiPen price

Company had increased cost of allergy device to $600 for two shots

Thu Aug 25 2016 - 16:03

Perrigo shares slide as drugmaker slashes full-year forecast again

Company sales have halved since the company rejected Mylan takeover offer late last year

Wed Aug 10 2016 - 20:49

Valeant is selling assets to help pay down long-term debt

Announcement by Canadian pharmaceutical company drives its shares up by 13%

Tue Aug 09 2016 - 19:10

Hedge funds set for worst first half since 2011 on turmoil

Industry suffers billions of dollars in withdrawals, with forecast for further shrinkage

Fri Jul 01 2016 - 12:38

For your diary

A round-up of business events happening this week

Mon Jun 06 2016 - 06:50

Valeant names Papa as its new CEO

Joseph Papa confirms position day after he resigns from the top spot at drugmaker Perrigo

Mon Apr 25 2016 - 14:43

Oil price surge prompts optimism for energy companies, pushing markets ahead

Iseq rises as stocks on Wall Street and in Europe lifted by energy companies

Fri Apr 08 2016 - 21:06

Valeant gets extra month from lenders to file annual report

Canadian pharma company says it remains well positioned to meet its obligations

Thu Apr 07 2016 - 20:08

Pfizer and Allergan confirm end to $160bn merger

New rules on corporate inversions see parties turn their attention elsewhere

Wed Apr 06 2016 - 17:21

Valeant fails to satisfy investors in ‘female viagra’

Sprout shareholders say company has set price too high, not marketing pill properly

Fri Mar 25 2016 - 16:07

Shake-up at Valeant signals stunning fall from grace for J Michael Pearson

Pharmaceutical giant faces a growing list of questions from investors and regulators

Tue Mar 22 2016 - 17:51

Valeant says chief executive Michael Pearson to step down

Company has appointed activist investor William Ackman to its board

Mon Mar 21 2016 - 13:19

Valeant Pharmaceuticals International cuts revenue forecast

The Canadian drugmaker cut its 2016 forecast by about 12% causing shares to plunge

Wed Mar 16 2016 - 01:00

European shares led lower by commodity stocks

Iseq ends lower with Bank of Ireland, Applegreen and Aryzta among the fallers

Wed Mar 16 2016 - 01:00

Valeant shares plunge 45 per cent on debt default risk

Canadian drugmaker cuts its revenue forecast by 12% and raises the spectre of default

Tue Mar 15 2016 - 14:36

Valeant insists key executive resigned and was not asked to go

Deb Jorn oversaw the Canadian pharmaceutical’s US dermatology business

Thu Mar 03 2016 - 21:58

Valeant shares slump on new SEC investigation

News comes as Canadian drug-maker pulled 2016 forecasts

Mon Feb 29 2016 - 21:28

Drugmaker Valeant pulls forecasts as Pearson returns

Chief executive back at the helm after two-month absence through illness but Robert Ingram retains chairman’s post

Mon Feb 29 2016 - 11:48

Johnson & Johnson loses $72m ‘talcum powder’ cancer case

First damages award over claims firm knew of ovarian cancer risks decades ago, company still faces 1,200 suits

Tue Feb 23 2016 - 16:39

Shares in Canadian drugmaker Valeant decline steeply for second day running

Wall Street Journal reports that pharmaceutical firm plans to restate earnings

Mon Feb 22 2016 - 23:29

One More Thing: Ingram in Valeant hot seat

Hospitalisation of Mike Pearson saw firm split his roles and bring Ingram to the chair

Fri Jan 15 2016 - 01:00

Ackman hedge fund sells down part of Valeant stake

Pershing Square Capital increased stake in beleaguered drug group last November but acts to generate tax loss for investors

Fri Jan 01 2016 - 12:41

Massive increases in medicine prices leave nasty taste

Pharma companies’ method of buying drug makers and racking up costs is a threat to R&D

Wed Nov 04 2015 - 09:30

Stocks in New York headed for best month in four years

Food group Aryzta’s shares drop again in Dublin following boardroom reshuffle

Sat Oct 31 2015 - 01:00

Joe Nocera: Valeant Pharmaceuticals looking like another Enron

Eye-popping growth and questionable acquisitions raise far too many questions

Wed Oct 28 2015 - 01:00